Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.54 USD | -0.65% | +12.41% | -16.30% |
05-21 | Biodesix, Inc. to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting | CI |
05-13 | TD Cowen Starts Biodesix With Buy Rating, $2.80 Price Target | MT |
Sales 2024 * | 66.9M 91.91M | Sales 2025 * | 82.78M 114M | Capitalization | 223M 307M |
---|---|---|---|---|---|
Net income 2024 * | -44M -60.45M | Net income 2025 * | -38M -52.21M | EV / Sales 2024 * | 3.34 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.7 x |
P/E ratio 2024 * |
-4.22
x | P/E ratio 2025 * |
-5.81
x | Employees | 217 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 34.9% |
Latest transcript on Biodesix, Inc.
1 day | -0.65% | ||
1 week | +12.41% | ||
Current month | +7.69% | ||
1 month | -2.53% | ||
3 months | +2.67% | ||
6 months | -1.91% | ||
Current year | -16.30% |
Managers | Title | Age | Since |
---|---|---|---|
Scott Hutton
CEO | Chief Executive Officer | 52 | - |
Robin Cowie
DFI | Director of Finance/CFO | 44 | 11-02-28 |
James R. Jett
CTO | Chief Tech/Sci/R&D Officer | - | 15-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Patience
CHM | Chairman | 76 | 08-05-31 |
Jack Schuler
BRD | Director/Board Member | 83 | 11-12-31 |
Jon Kayyem
BRD | Director/Board Member | 60 | 21-12-05 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-12 | 1.54 | -0.65% | 197,832 |
24-06-11 | 1.55 | +11.51% | 279,687 |
24-06-10 | 1.39 | +4.51% | 171,137 |
24-06-07 | 1.33 | +2.31% | 94,636 |
24-06-06 | 1.3 | -5.11% | 43,807 |
Delayed Quote Nasdaq, June 12, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.30% | 223M | |
-21.29% | 8.05B | |
+77.60% | 4.56B | |
+8.36% | 2.74B | |
-2.80% | 2.65B | |
-49.62% | 2.02B | |
-13.10% | 1.8B | |
-20.79% | 1.46B | |
+16.24% | 1.2B | |
-44.65% | 1.13B |
- Stock Market
- Equities
- BDSX Stock